About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Biomedical Research in Melanoma group is interested in skin cancer. We investigate the molecular causes for these diseases to design effective therapies against them. Our research is done in close proximity to patients, where our goal is to translate our discoveries as fast as possible to the clinic. To that end, we have a multidisciplinary group that associate dermatologists, oncologists, pathologists and basic-scientists that ask relevant clinical questions that need biological answers. Our workflow contemplates information obtained from patients (genetic information, clinical history, functional data…) that is translated into animal models (genetic modified mouse models, PDX…) and in vitro experiments to answer the formulated questions. These results are used to design novel therapeutic approaches, including drug development and preclinical studies that ultimately will be translated to patients.
The main lines of investigation are: • Molecular mechanisms involved in melanoma development and progression, • Targeting metabolism for melanoma treatment, • The mechanisms of resistance to immunotherapy.
IP: Juan Angel Recio Conde Collaborators: Laia Perez Lasarte, Yuxin Ding Funding agency: Fundació Institut de Recerca HUVH Funding: 69188.74 Reference: VPHD/YUXUNG_D Duration: 01/09/2023 - 31/08/2026
IP: Juan Angel Recio Conde Collaborators: Discovering intratumoral immune-cell resistance mechanisms to immunotherapy response Funding agency: Fundació "La Caixa" Funding: 115092 Reference: CAIXA/INPHINIT/2022/ORSENIGO Duration: 01/11/2022 - 31/10/2025
IP: Juan Angel Recio Conde Collaborators: Paula Granado Martinez, Kimberley Anne McGrail Fernández, Carlos González Cruz, Vicente García-Patos Briones, Eva Muñoz Couselo Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 60000 Reference: 2021 SGR 00653 Duration: 01/01/2022 - 30/06/2025
IP: Ernesto Trallero Araguas Collaborators: Albert Selva O'Callaghan, Raul Tortosa Mendez, Albert Gil Vila, Gloria Aparicio Español, Adria Aterido Ballonga, Hugo Fernando Avalos Bogado Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI22/00708 Duration: 01/01/2023 - 31/12/2025
The study reveals that if the exposure of newborns to solar radiation of sufficient intensity to provoke a skin reaction is simultaneous with the activation of the BRAFv600E gene, it can trigger an uncontrolled proliferation of cancer cells.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.
